Please login to the form below

Not currently logged in
Email:
Password:

Kynamro

This page shows the latest Kynamro news and features for those working in and with pharma, biotech and healthcare.

Isis renamed Ionis to sidestep militant association

Isis renamed Ionis to sidestep militant association

Isis has already brought one drug to market - Sanofi-partnered Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH) - and has three candidates in late-stage development.

Latest news

  • Janssen partners with Isis on stomach conditions Janssen partners with Isis on stomach conditions

    Janssen – the pharma subsidiary of Johnson &Johnson (J&J) - chose Isis to work with due to its experience in the area, which includes the development of lipid-lowering medicine Kynamro (mipomersen ... Kynamro, which was approved by the US FDA at the

  • Biogen Idec gets exclusive access to Isis' neurology R&D Biogen Idec gets exclusive access to Isis' neurology R&D

    In January Isis and partner Sanofi won approval in the US for Kynamro (mipomersen) to treat the rare cardiovascular disease homozygous familial hypercholesterolaemia, the first antisense drug to reach market since ... The company suffered a setback last

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    FCS affects around 3, 000 to 5, 000 patients worldwide. Isis' lead programme at the moment is Kynamro (mipomersen), an antisense drug for elevated cholesterol that is partnered with Sanofi and

  • US approval for Sanofi’s Kynamro in genetic cholesterol disorder US approval for Sanofi’s Kynamro in genetic cholesterol disorder

    Regulators in the US have approved Sanofi/Isis Pharmaceuticals' add-on cholesterol treatment Kynamro a month after it was turned down in Europe due to safety concerns. ... Today's FDA approval of Kynamro is great news for patients with HoFH who are in

  • Sanofi has 65 new compounds in development, says R&D chief Sanofi has 65 new compounds in development, says R&D chief

    In the US, Sanofi is waiting for an FDA decision on Kynamro (mipomersen sodium) for homozygous familial hypercholesterolaemia after the drug was turned down by the CHMP last month, as well

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics